Wuhan Keqian Biology Co.,Ltd

Equities

688526

CNE1000042Q8

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
17.39 CNY -1.31% Intraday chart for Wuhan Keqian Biology Co.,Ltd +4.32% -14.67%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tranche Update on Wuhan Keqian Biology Co.,Ltd's Equity Buyback Plan announced on February 22, 2024. CI
Wuhan Keqian Biology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Wuhan Keqian Biology Co.,Ltd announces an Equity Buyback for CNY 50 million worth of its shares. CI
Wuhan Keqian Biology Co.,Ltd authorizes a Buyback Plan. CI
Wuhan Keqian Biology Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Certain A Shares of Wuhan Keqian Biology Co.,Ltd are subject to a Lock-Up Agreement Ending on 22-SEP-2023. CI
Wuhan Keqian Biology Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Wuhan Keqian Biology Elects Chairman, Vice Chairman MT
Wuhan Keqian Biology Co.,Ltd cancelled the transaction announced on October 28, 2022 CI
Wuhan Keqian Biology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Wuhan Keqian Biology Co.,Ltd announces decision of Shareholder/Board on the transaction CI
Wuhan Keqian Biology’s New Swine Vaccines Obtain Registration Certificates in China MT
Wuhan Keqian Biology Partners With University for Vaccine Development MT
Wuhan Keqian Biology Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Wuhan Keqian Biology Co.,Ltd announced a financing transaction CI
Certain A Shares of Wuhan Keqian Biology Co.,Ltd are subject to a Lock-Up Agreement Ending on 22-SEP-2022. CI
Wuhan Keqian Biology Co.,Ltd(XSSC:688526) added to S&P Global BMI Index CI
Wuhan Keqian Biology Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Wuhan Keqian Biology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Wuhan Keqian Biology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
China shares fall on tech weakness; China Mobile edges higher in Shanghai debut RE
Wuhan Keqian Biology Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Certain A Shares of Wuhan Keqian Biology Co.,Ltd are subject to a Lock-Up Agreement Ending on 22-SEP-2021. CI
Wuhan Keqian Biology Co.,Ltd(SHSE:688526) added to Shanghai Stock Exchange Composite Index CI
Wuhan Keqian Biology Co.,Ltd(SHSE:688526) added to Shanghai Stock Exchange A Share Index CI
Chart Wuhan Keqian Biology Co.,Ltd
More charts
Wuhan Keqian Biology Co Ltd is a China-based company mainly engaged in the research and development, production, sales of veterinary biological products and the provision of animal epidemic prevention technical services. The Company's main products are vaccines for swine and poultry. The Company mainly conducts its businesses within the China market.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
17.39 CNY
Average target price
24.75 CNY
Spread / Average Target
+42.32%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688526 Stock
  4. News Wuhan Keqian Biology Co.,Ltd
  5. Wuhan Keqian Biology Partners With University for Vaccine Development